000			01313 a2200361 4500
005			20250515061335.0
264		0	_c20071004
008			200710s 0 0 eng d
022			_a0950-9232
024	7		_a10.1038/sj.onc.1210383 _2doi
040			_aNLM _beng _cNLM
100	1		_aIrmer, D
245	0	0	_aEGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. _h[electronic resource]
260			_bOncogene _cAug 2007
300			_a5693-701 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aErbB Receptors _xantagonists & inhibitors
650	0	4	_aGefitinib
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMutation _xgenetics
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProtein Structure, Tertiary
650	0	4	_aQuinazolines _xtherapeutic use
700	1		_aFunk, J O
700	1		_aBlaukat, A
773	0		_tOncogene _gvol. 26 _gno. 39 _gp. 5693-701
856	4	0	_uhttps://doi.org/10.1038/sj.onc.1210383 _zAvailable from publisher's website
999			_c16909956 _d16909956